SciSparc (NASDAQ:SPRC) Trading Down 6.7% – Time to Sell?

SciSparc Ltd. (NASDAQ:SPRC) shares dropped 6.7% on Tuesday . The company traded as low as $1.35 and last traded at $1.39. Approximately 80,904 shares were traded during trading, a decline of 98% from the average daily volume of 3,537,038 shares. The stock had previously closed at $1.49.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Wall Street Zen upgraded shares of SciSparc to a “sell” rating in a research note on Saturday, September 13th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of SciSparc in a report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has a consensus rating of “Sell”.

SciSparc Trading Down 6.7%

The firm has a fifty day simple moving average of $2.62 and a two-hundred day simple moving average of $4.33.

SciSparc (NASDAQ:SPRC) last issued its quarterly earnings results on Tuesday, November 18th. The company reported ($3.08) EPS for the quarter. The firm had revenue of $0.23 million during the quarter.

About SciSparc

SciSparc AG is a clinical‐stage medical technology company focused on the development and commercialization of extracorporeal shock wave–based neuromodulation devices. Founded in 2016 and headquartered in Switzerland, the company applies proprietary low‐intensity shock wave technology to noninvasively stimulate neural tissue. SciSparc completed its initial public offering on the NASDAQ in 2021 under the ticker SPRC, securing funding to advance its clinical pipeline.

The company’s lead product, the TR100 system, delivers transcranial shock wave stimulation (tSWS) designed to target areas of the brain associated with motor control and cognitive function.